# US 2021/0261645 A1 · Bispecific t cell engager and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0261645 A1
- Document ID: US20210261645A1
- Status: Published application
- Kind: A1
- Application number: 17/057,957
- Filed: 2019-05-23
- Published: 2021-08-26
- Earliest claimed: 2018-05-23
- Assignees: Manysmart Therapeutics, Inc.
- Applicants: Manysmart Therapeutics, Inc.
- Inventors: HSIN-YI HUANG; Cheng Hao LIAO
- Web page: https://patentgrep.com/patent/US20210261645A1

## CPC

- C07K 14/70535: {Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)}
- A61K 39/44: Antibodies bound to carriers
- A61P 31/22: for herpes viruses
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07K 16/085: Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C07K 16/283: {against Fc-receptors, e.g. CD16, CD32, CD64 (CD23 C07K16/2851)}
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/2887: {against CD20}
- C07K 16/32: against translation products of oncogenes
- C12N 15/62: DNA sequences coding for fusion proteins
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- A61K 2039/5256: {expressing foreign proteins}
- A61K 2039/585: {wherein the target is cancer}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2319/02: containing a signal sequence
- C07K 2319/21: containing a His-tag
- C07K 2319/32: fusions with soluble part of a cell surface receptor, "decoy receptors"
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A novel fusion protein to overcome the current difficulties related to application of monoclonal antibodies in disease treatment and in other fields, particularly those requiring ADCC, e.g. for depletion of tumor cells, virally-infected cells, or immune-modulating cells, etc. One example of the fusion protein is an extracellular domain of a high-affinity variant of human CD 16 A fused to an anti-CD3 antibody or its antigen-binding fragment thereof that specifically binds to an epitope on human CD3 or a fragment thereof.

## Claims

### Claim 1

A fusion protein comprising:
an extracellular domain of human CD16A; and
an antibody or antigen-binding fragment thereof that specifically binds to an epitope on human CD3 or a fragment thereof.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The fusion protein according to claim 1, wherein the extracellular domain of CD16A has an amino acid sequence of SEQ ID NO: 2 or a substantially similar sequence thereof.

### Claim 4 (depends on 1)

The fusion protein according to claim 1, wherein the antibody or antigen-binding fragment thereof is an anti-CD3 single-chain variable fragment.

### Claim 5 (depends on 1)

The fusion protein according to claim 1, wherein the antibody or antigen-binding fragment thereof has an amino acid sequence of SEQ ID NO: 4 or a substantially similar sequence thereof.

### Claim 6 (depends on 1)

The fusion protein according to claim 1, wherein the extracellular domain of CD16A directly links to the antibody or antigen-binding fragment thereof.

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The fusion protein according to claim 1, which further comprises a protein purification tag.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

A polynucleotide encoding the fusion protein according to claim 1.

### Claim 12 (depends on 7)

The polynucleotide according to claim 7, which comprises a fragment encoding the extracellular domain of CD16A and has a nucleic acid sequence of SEQ ID NO: 1 or a substantially identical sequence thereof.

### Claim 13 (depends on 7)

The polynucleotide according to claim 7, which comprises a fragment encoding the antibody or antigen-binding fragment thereof and has a nucleic acid sequence of SEQ ID NO: 3 or a substantially identical sequence thereof.

### Claim 14 (depends on 7)

The polynucleotide according to claim 7, which further comprises a fragment encoding a secretion signal peptide and has a nucleic acid sequence of SEQ ID NO: 5 or a substantially identical sequence thereof.

### Claim 15 (depends on 7)

The polynucleotide according to claim 7, which further comprises a fragment encoding a protein purification tag.

### Claim 16 (depends on 7)

The polynucleotide according to claim 7, which has a nucleic acid sequence of SEQ ID NO: 7 or a substantially identical sequence thereof.

### Claim 17 (depends on 7)

The polynucleotide according to claim 7, which is contained in an adeno-associated virus vector.

### Claim 18 (depends on 7)

A host cell comprising the polynucleotide according to claim 7.

### Claim 19 (depends on 14)

The host cell according to claim 14, wherein the polynucleotide is contained in an adeno-associated virus vector.

### Claim 20 (depends on 1)

A method for inducing antibody-dependent cellular cytotoxicity in a subject in need, comprising administrating the subject a pharmaceutical composition comprising a therapeutically effective amount of the fusion protein according to claim 1 and optionally a pharmaceutically acceptable carrier or excipient.

### Claim 21 (depends on 16, 20)

The method according to claim 16, wherein the pharmaceutical composition according to claim 20, which further comprises an antibody or antibodies.

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24 (depends on 1)

A method for treating a cancer, an infectious disease, an autoimmune disease, a graft versus host disease, or a post-transplantation lymphoproliferative disease in a subject in need, comprising administrating the subject a pharmaceutical composition comprising a therapeutically effective amount of the fusion protein according to claim 1 and optionally a pharmaceutically acceptable carrier or excipient.

### Claim 25 (depends on 18)

The method according to claim 18, wherein the pharmaceutical composition further comprises an antibody or antibodies.
